World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
101235
World Ranking
5033
National Ranking
193

John B. A. G. Haanen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John B. A. G. Haanen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 597 publications — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John B. A. G. Haanen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John B. A. G. Haanen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John B. A. G. Haanen is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands. Their academic contributions primarily focus on oncology within the broader field of medicine. The main areas of study include oncology, molecular biology, immunology, pulmonary and respiratory medicine, and radiology-related imaging techniques.

Their research covers several key topics including:

  • Cancer immunotherapy and biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and immune responses
  • Cutaneous melanoma detection and management
  • Melanoma and MAPK pathways
  • Renal cell carcinoma treatment
  • Cancer genomics and diagnostics

John B. A. G. Haanen has published extensively in a range of scientific journals. Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • ESMO Open
  • Nature Medicine

Some of their recent notable papers are:

  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers, 2020, Nature Medicine

Among their frequent co-authors are:

  • Christian U. Blank
  • Ellen Kapiteijn
  • Karijn P.M. Suijkerbuijk
  • Geke A.P. Hospers
  • Maureen J.B. Aarts

The scientist's work contributes notably to the areas of cancer treatment and immunotherapy, addressing both molecular and clinical aspects. Their research spans from understanding immunological mechanisms to clinical management of advanced cancers including melanoma and renal cell carcinoma.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

    R de Waal Malefyt;J Haanen;H Spits;M G Roncarolo

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

    Myriam Chalabi;Lorenzo F Fanchi;Krijn K Dijkstra;José G Van den Berg

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

    Hanjie Li;Anne M. van der Leun;Ido Yofe;Yaniv Lubling

  • Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

    Krijn K Dijkstra;Chiara M Cattaneo;Fleur Weeber;Myriam Chalabi

  • Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

    Nienke van Rooij;Marit M. van Buuren;Daisy Philips;Arno Velds

  • Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

    Chong Sun;Liqin Wang;Sidong Huang;Guus J. J. E. Heynen

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • The “cancer immunogram”

    Christian U. Blank;John B. Haanen;Antoni Ribas;Ton N. Schumacher

  • Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

    Leonie Voorwerk;Maarten Slagter;Hugo M. Horlings;Karolina Sikorska

  • Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Christian U. Blank;Elisa A. Rozeman;Lorenzo F. Fanchi;Karolina Sikorska

Frequent Co-Authors

Ton N. M. Schumacher
Ton N. M. Schumacher Antoni van Leeuwenhoek Hospital
Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Jos H. Beijnen
Jos H. Beijnen Utrecht University
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Reinhard Dummer
Reinhard Dummer University of Zurich
Simon Horenblas
Simon Horenblas Antoni van Leeuwenhoek Hospital
Caroline Robert
Caroline Robert University of Paris-Saclay
Paul Lorigan
Paul Lorigan University of Manchester
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career doesn't always mean following the path to becoming a physician. There are many online degree options and unique career pathways for those passionate about healthcare. For students eager to advance quickly, fast track LPN programs provide a streamlined route into nursing, allowing you to start working sooner.

For registered nurses aiming to take their education further, DNP online programs offer a flexible way to earn a Doctor of Nursing Practice without sacrificing your current job. Those interested in mental health might consider the fastest psychiatric nurse practitioner program to quickly specialize in this vital field.

Additionally, for individuals who see themselves in leadership or administrative roles, enrolling in a health administration degree online can open doors to behind-the-scenes positions that are critical to hospital and clinic operations. These online programs offer flexibility, affordability, and the chance to make a meaningful impact on the healthcare system.

Best Scientists Citing John B. A. G. Haanen

Trending Scientists